Sign In

Login

Password

Forgot Password ? Sign Up

Olaparyb (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Olaparyb" in Polish language version.

refsWebsite
Global rank Polish rank
21nih.gov
4th place
7th place
20doi.org
2nd place
6th place
3web.archive.org
1st place
1st place

doi.org

dx.doi.org

  • Junko Murai i inni, Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors, „Cancer Research”, 72 (21), 2012, s. 5588–5599, DOI: 10.1158/0008-5472.CAN-12-2753, PMID: 23118055, PMCID: PMC3528345 (ang.).
  • Joline S.J. Lim, David S.P. Tan, Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors, „Cancers”, 9 (8), 2017, DOI: 10.3390/cancers9080109, PMID: 28829366, PMCID: PMC5575612 (ang.).
  • Karolina N. Dziadkowiec i inni, PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting, „Menopause Review”, 15 (4), 2016, s. 215–219, DOI: 10.5114/pm.2016.65667, PMID: 28250726, PMCID: PMC5327624 (ang.).
  • Keith A. Menear i inni, 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1, „Journal of Medicinal Chemistry”, 51 (20), 2008, s. 6581–6591, DOI: 10.1021/jm8001263, PMID: 18800822 (ang.).
  • Sylvia Bochum, Stephanie Berger, Uwe M. Martens, Olaparib, „Recent Results in Cancer Research”, 211, 2018, s. 217–233, DOI: 10.1007/978-3-319-91442-8_15, PMID: 30069770 (ang.).
  • Ying Chen, Hui Du, The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others, „Biomedicine & Pharmacotherapy”, 99, 2018, s. 552–560, DOI: 10.1016/j.biopha.2018.01.094, PMID: 29895102 (ang.).
  • Michèle Rouleau i inni, PARP inhibition: PARP1 and beyond, „Nature Reviews. Cancer”, 10 (4), 2010, s. 293–301, DOI: 10.1038/nrc2812, PMID: 20200537, PMCID: PMC2910902 (ang.).
  • Hannah Farmer i inni, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, „Nature”, 434 (7035), 2005, s. 917–921, DOI: 10.1038/nature03445, PMID: 15829967 (ang.).
  • Maksymilian Artur Kruczała, Aleksandra Grela-Wojewoda, Ida Cedrych, Inhibitory PARP w terapii raka jajnika, „Ginekologia Polska”, 87 (2), 2016, s. 131–134, DOI: 10.17772/gp/59268, PMID: 27306290.
  • J.E. Frampton, Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer, „BioDrugs”, 29 (2), 2015, s. 143–150, DOI: 10.1007/s40259-015-0125-6, PMID: 25899311 (ang.).
  • Jonathan Ledermann i inni, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, „The Lancet Oncology”, 15 (8), 2014, s. 852–861, DOI: 10.1016/S1470-2045(14)70228-1, PMID: 24882434 (ang.).
  • Jonathan Ledermann i inni, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, „The New England Journal of Medicine”, 366 (15), 2012, s. 1382–1392, DOI: 10.1056/NEJMoa1105535, PMID: 22452356 (ang.).
  • Bella Kaufman i inni, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, „Journal of Clinical Oncology”, 33 (3), 2015, s. 244–250, DOI: 10.1200/JCO.2014.56.2728, PMID: 25366685, PMCID: PMC6057749 (ang.).
  • Nasim Mavaddat i inni, Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), „Cancer Epidemiology, Biomarkers & Prevention”, 21 (1), 2012, s. 134–147, DOI: 10.1158/1055-9965.EPI-11-0775, PMID: 22144499, PMCID: PMC3272407 (ang.).
  • Deann P. Atchley i inni, Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer, „Journal of Clinical Oncology”, 26 (26), 2008, s. 4282–4288, DOI: 10.1200/JCO.2008.16.6231, PMID: 18779615 (ang.).
  • Andrew Tutt i inni, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial, „The Lancet”, 376 (9737), 2010, s. 235–244, DOI: 10.1016/S0140-6736(10)60892-6, PMID: 20609467 (ang.).
  • Karen A. Gelmon i inni, Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study, „The Lancet Oncology”, 12 (9), 2011, s. 852–861, DOI: 10.1016/S1470-2045(11)70214-5, PMID: 21862407 (ang.).
  • Mark Robson i inni, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation, „The New England Journal of Medicine”, 377 (6), 2017, s. 523–533, DOI: 10.1056/NEJMoa1706450, PMID: 28578601 (ang.).
  • Francesca De Felice i inni, Defective DNA repair mechanisms in prostate cancer: impact of olaparib, „Drug Design, Development and Therapy”, 11, 2017, s. 547–552, DOI: 10.2147/DDDT.S110264, PMID: 28280302, PMCID: PMC5338854 (ang.).
  • Joaquin Mateo i inni, DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer, „The New England Journal of Medicine”, 373 (18), 2015, s. 1697–1708, DOI: 10.1056/NEJMoa1506859, PMID: 26510020, PMCID: PMC5228595 (ang.).

nih.gov

ncbi.nlm.nih.gov

  • Junko Murai i inni, Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors, „Cancer Research”, 72 (21), 2012, s. 5588–5599, DOI: 10.1158/0008-5472.CAN-12-2753, PMID: 23118055, PMCID: PMC3528345 (ang.).
  • Joline S.J. Lim, David S.P. Tan, Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors, „Cancers”, 9 (8), 2017, DOI: 10.3390/cancers9080109, PMID: 28829366, PMCID: PMC5575612 (ang.).
  • Karolina N. Dziadkowiec i inni, PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting, „Menopause Review”, 15 (4), 2016, s. 215–219, DOI: 10.5114/pm.2016.65667, PMID: 28250726, PMCID: PMC5327624 (ang.).
  • Keith A. Menear i inni, 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1, „Journal of Medicinal Chemistry”, 51 (20), 2008, s. 6581–6591, DOI: 10.1021/jm8001263, PMID: 18800822 (ang.).
  • Sylvia Bochum, Stephanie Berger, Uwe M. Martens, Olaparib, „Recent Results in Cancer Research”, 211, 2018, s. 217–233, DOI: 10.1007/978-3-319-91442-8_15, PMID: 30069770 (ang.).
  • Ying Chen, Hui Du, The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others, „Biomedicine & Pharmacotherapy”, 99, 2018, s. 552–560, DOI: 10.1016/j.biopha.2018.01.094, PMID: 29895102 (ang.).
  • Michèle Rouleau i inni, PARP inhibition: PARP1 and beyond, „Nature Reviews. Cancer”, 10 (4), 2010, s. 293–301, DOI: 10.1038/nrc2812, PMID: 20200537, PMCID: PMC2910902 (ang.).
  • Hannah Farmer i inni, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, „Nature”, 434 (7035), 2005, s. 917–921, DOI: 10.1038/nature03445, PMID: 15829967 (ang.).
  • Maksymilian Artur Kruczała, Aleksandra Grela-Wojewoda, Ida Cedrych, Inhibitory PARP w terapii raka jajnika, „Ginekologia Polska”, 87 (2), 2016, s. 131–134, DOI: 10.17772/gp/59268, PMID: 27306290.
  • J.E. Frampton, Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer, „BioDrugs”, 29 (2), 2015, s. 143–150, DOI: 10.1007/s40259-015-0125-6, PMID: 25899311 (ang.).
  • Jonathan Ledermann i inni, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, „The Lancet Oncology”, 15 (8), 2014, s. 852–861, DOI: 10.1016/S1470-2045(14)70228-1, PMID: 24882434 (ang.).
  • Jonathan Ledermann i inni, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, „The New England Journal of Medicine”, 366 (15), 2012, s. 1382–1392, DOI: 10.1056/NEJMoa1105535, PMID: 22452356 (ang.).
  • Bella Kaufman i inni, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, „Journal of Clinical Oncology”, 33 (3), 2015, s. 244–250, DOI: 10.1200/JCO.2014.56.2728, PMID: 25366685, PMCID: PMC6057749 (ang.).
  • Nanna H. Sulai, Antoinette R. Tan, Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer, „Clinical Advances in Hematology & Oncology”, 16 (7), 2018, s. 491–501, PMID: 30067621 [zarchiwizowane 2018-08-03] (ang.).
  • Nasim Mavaddat i inni, Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), „Cancer Epidemiology, Biomarkers & Prevention”, 21 (1), 2012, s. 134–147, DOI: 10.1158/1055-9965.EPI-11-0775, PMID: 22144499, PMCID: PMC3272407 (ang.).
  • Deann P. Atchley i inni, Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer, „Journal of Clinical Oncology”, 26 (26), 2008, s. 4282–4288, DOI: 10.1200/JCO.2008.16.6231, PMID: 18779615 (ang.).
  • Andrew Tutt i inni, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial, „The Lancet”, 376 (9737), 2010, s. 235–244, DOI: 10.1016/S0140-6736(10)60892-6, PMID: 20609467 (ang.).
  • Karen A. Gelmon i inni, Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study, „The Lancet Oncology”, 12 (9), 2011, s. 852–861, DOI: 10.1016/S1470-2045(11)70214-5, PMID: 21862407 (ang.).
  • Mark Robson i inni, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation, „The New England Journal of Medicine”, 377 (6), 2017, s. 523–533, DOI: 10.1056/NEJMoa1706450, PMID: 28578601 (ang.).
  • Francesca De Felice i inni, Defective DNA repair mechanisms in prostate cancer: impact of olaparib, „Drug Design, Development and Therapy”, 11, 2017, s. 547–552, DOI: 10.2147/DDDT.S110264, PMID: 28280302, PMCID: PMC5338854 (ang.).
  • Joaquin Mateo i inni, DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer, „The New England Journal of Medicine”, 373 (18), 2015, s. 1697–1708, DOI: 10.1056/NEJMoa1506859, PMID: 26510020, PMCID: PMC5228595 (ang.).

web.archive.org